source
- Amgen and academic centers discuss FDA pilot to accelerate first-in-human trialsThe U.S. Food and Drug Administration is working with industry and research institutions on a pilot program aimed at speeding first-in-human studies. The effort is intended to counter the rapid tim…
- Inhalable modified tRNA restores lung protein function in cystic fibrosis mice, shows promise for genetic diseasesUniversity of Toronto scientists have shown that an inhalable form of modified transfer RNA can safely reach the lungs of mice carrying a nonsense mutation that causes cystic fibrosis. The treatmen…